Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations

Weijie Ma; Jay Gong; Jidong Shan; Debbie Lewis; Wenwu Xiao; Elizabeth H. Moore; Yanhong Zhang; Jamie Hung; Nicole Z. Mans; Sixi Wei; Jenna Welborn; Nicholas S. Stollenwerk; Kit S. Lam; Tianhong Li

doi:10.1200/PO.18.00076

Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations

Weijie Ma, Jay Gong, Jidong Shan, Debbie Lewis, Wenwu Xiao, Elizabeth H. Moore, Yanhong Zhang, Jamie Hung, Nicole Z. Mans, Sixi Wei, Jenna Welborn, Nicholas S. Stollenwerk, Kit S. Lam, Tianhong Li

Genetics

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Journal	JCO Precision Oncology
Volume	2
DOIs	https://doi.org/10.1200/PO.18.00076
State	Published - Jan 1 2018

ASJC Scopus subject areas

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/PO.18.00076

Cite this

Ma, W., Gong, J., Shan, J., Lewis, D., Xiao, W., Moore, E. H., Zhang, Y., Hung, J., Mans, N. Z., Wei, S., Welborn, J., Stollenwerk, N. S., Lam, K. S., & Li, T. (2018). Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations. JCO Precision Oncology, 2. https://doi.org/10.1200/PO.18.00076

Ma, W, Gong, J, Shan, J, Lewis, D, Xiao, W, Moore, EH, Zhang, Y, Hung, J, Mans, NZ, Wei, S, Welborn, J, Stollenwerk, NS, Lam, KS & Li, T 2018, 'Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations', JCO Precision Oncology, vol. 2. https://doi.org/10.1200/PO.18.00076

@article{e52320b2a31c4019a4ff7d66d8c87e66,

title = "Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations",

author = "Weijie Ma and Jay Gong and Jidong Shan and Debbie Lewis and Wenwu Xiao and Moore, {Elizabeth H.} and Yanhong Zhang and Jamie Hung and Mans, {Nicole Z.} and Sixi Wei and Jenna Welborn and Stollenwerk, {Nicholas S.} and Lam, {Kit S.} and Tianhong Li",

year = "2018",

month = jan,

day = "1",

doi = "10.1200/PO.18.00076",

language = "English (US)",

volume = "2",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations

AU - Ma, Weijie

AU - Gong, Jay

AU - Shan, Jidong

AU - Lewis, Debbie

AU - Xiao, Wenwu

AU - Moore, Elizabeth H.

AU - Zhang, Yanhong

AU - Hung, Jamie

AU - Mans, Nicole Z.

AU - Wei, Sixi

AU - Welborn, Jenna

AU - Stollenwerk, Nicholas S.

AU - Lam, Kit S.

AU - Li, Tianhong

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85056089189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056089189&partnerID=8YFLogxK

U2 - 10.1200/PO.18.00076

DO - 10.1200/PO.18.00076

M3 - Article

AN - SCOPUS:85056089189

SN - 2473-4284

VL - 2

JO - JCO Precision Oncology

JF - JCO Precision Oncology

ER -

Safety and efficacy of Osimertinib in the treatment of a patient with metastatic lung cancer and concurrent somatic EGFR L858R and germline EGFR T790M mutations

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this